Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

676496 VEGF Inhibitor, CBO-P11 - Calbiochem

VEGF Inhibitor, CBO-P11, is a macrocyclic peptide derived from residues 79-93 of VEGF. Mediates VEGF binding to VEGFR-2. Blocks VEGF165 binding to VEGFR1 and 2 (IC50 = 700 nM & 1.3 µM, respectively).

VEGF Inhibitor, CBO-P11 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: Cyclo-VEGI, cyclic(D-F-PQIMRIKPHQGQHIGE), D-Phe-Pro(79-93), VEGFR Tyrosine Kinase Inhibitor XX, VEGFR2 Kinase Inhibitor XVI

Primary Target: Blocks the binding of VEGF165 to its receptors
676496
Purchase on Sigma-Aldrich

Overview

Replacement Information

Key Spec Table

Empirical Formula
C₉₀H₁₄₀N₂₈O₂₂S

Products

Catalogue NumberPackaging Qty/Pack
676496-1MG Plastová ampulka 1 mg
Description
OverviewA macrocyclic 17-amino acid peptide derived from residues 79 - 93 of vascular endothelial growth factor that mediate its binding to VEGFR-2. It blocks the binding of VEGF165 to its receptors (IC50 = 700 nM for VEGFR1, 1.3 µM for VEGFR2) and exhibits anti-angiogenic activity as well as other VEGFR-mediated cellular functions, such as proliferation (IC50 = 5.8 µM), migration (IC50 = 8.2 µM), and activation of MAP kinases. Its anti-angiogenic activity has been successfully demonstrated in vivo using chick embryos and nude mice tumor models of human intracranial and syngeneic glioma.
Catalogue Number676496
Brand Family Calbiochem®
SynonymsCyclo-VEGI, cyclic(D-F-PQIMRIKPHQGQHIGE), D-Phe-Pro(79-93), VEGFR Tyrosine Kinase Inhibitor XX, VEGFR2 Kinase Inhibitor XVI
References
ReferencesZilberberg, L., et al. 2003. J. Biol. Chem. 278, 35564.
Product Information
ATP CompetitiveN
FormWhite lyophilized solid
FormulationSupplied as a trifluoroacetate salt.
Hill FormulaC₉₀H₁₄₀N₂₈O₂₂S
Chemical formulaC₉₀H₁₄₀N₂₈O₂₂S
Hygroscopic Hygroscopic
ReversibleN
Quality LevelMQ100
Applications
ApplicationVEGF Inhibitor, CBO-P11, is a macrocyclic peptide derived from residues 79-93 of VEGF. Mediates VEGF binding to VEGFR-2. Blocks VEGF165 binding to VEGFR1 and 2 (IC50 = 700 nM & 1.3 µM, respectively).
Biological Information
Primary TargetBlocks the binding of VEGF165 to its receptors
Primary Target IC<sub>50</sub>700 nM for VEGFR1, 1.3 µM for VEGFR2
Purity≥97% by HPLC
Physicochemical Information
Cell permeableN
Peptide Sequencecyclic(D-Phe-Pro-Gln-Ile-Met-Arg-Ile-Lys-Pro-His-Gln-Gly-Gln-His-Ile-Gly-Glu)
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Shipped with Blue Ice or with Dry Ice
Toxicity Carcinogenic / Teratogenic
Storage -20°C
Protect from Light Protect from light
Hygroscopic Hygroscopic
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
676496-1MG 04055977260489

Documentation

VEGF Inhibitor, CBO-P11 - Calbiochem MSDS

Title

Safety Data Sheet (SDS) 

VEGF Inhibitor, CBO-P11 - Calbiochem Certificates of Analysis

TitleLot Number
676496

References

Reference overview
Zilberberg, L., et al. 2003. J. Biol. Chem. 278, 35564.

Citations

Title
  • Vivian Y. Shin, et al. (2005) Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Molecular Cancer Research 3, 607-615.
    		•
    Data Sheet

    Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

    Revision16-September-2008 RFH
    SynonymsCyclo-VEGI, cyclic(D-F-PQIMRIKPHQGQHIGE), D-Phe-Pro(79-93), VEGFR Tyrosine Kinase Inhibitor XX, VEGFR2 Kinase Inhibitor XVI
    DescriptionA macrocyclic, 17-amino acid peptide derived from residues 79-93 of vascular endothelial growth factor (VEGF) that mediates the binding of VEGF to its receptor, VEGFR-2. Blocks the binding of VEGF165 to its receptors (IC50 = 70 nM for VEGFR-1, 1.3 µM for VEGFR-2) and exhibits anti-angiogenic properties. Also reported to block other VEGF-mediated cellular functions such as proliferation (IC50 = 5.8 µM), migration (IC50 = 8.2 µM), and activation of MAP kinases. Also reported to exhibit anti-angiogenic properties in vivo using chick embryo and nude mouse tumor models of human intracranial and syngeneic glioma.
    FormWhite lyophilized solid
    FormulationSupplied as a trifluoroacetate salt.
    Intert gas (Yes/No) Packaged under inert gas
    Chemical formulaC₉₀H₁₄₀N₂₈O₂₂S
    Peptide Sequencecyclic(D-Phe-Pro-Gln-Ile-Met-Arg-Ile-Lys-Pro-His-Gln-Gly-Gln-His-Ile-Gly-Glu)
    Purity≥97% by HPLC
    SolubilityDMSO (5 mg/ml) or H₂O
    Storage Protect from light
    -20°C
    Hygroscopic
    Do Not Freeze Ok to freeze
    Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
    Toxicity Carcinogenic / Teratogenic
    ReferencesZilberberg, L., et al. 2003. J. Biol. Chem. 278, 35564.
    Citation
  • Vivian Y. Shin, et al. (2005) Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Molecular Cancer Research 3, 607-615.
    		•